{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:00:29Z","timestamp":1778691629543,"version":"3.51.4"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010842","name":"Guangzhou Municipal Health and Family Planning Commission","doi-asserted-by":"publisher","award":["20191A1515011263"],"award-info":[{"award-number":["20191A1515011263"]}],"id":[{"id":"10.13039\/501100010842","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Immune checkpoint blockade inhibitor (ICI) therapy offers significant survival benefits for malignant melanoma. However, some patients were observed to be in disease progression after the first few treatment cycles. As such, it is urgent to find convenient and accessible indicators that assess whether patients can benefit from ICI therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the training cohort, flow cytometry was used to determine the absolute values of 66 immune cell subsets in the peripheral blood of melanoma patients (n=29) before treatment with anti-PD-1 inhibitors. The least absolute shrinkage and selection operator (LASSO) Cox regression model was followed for the efficacy of each subset in predicting progression-free survival. Then we validated the performance of the selected model in validation cohorts (n=20), and developed a nomogram for clinical use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A prognostic immune risk score composed of CD1c<jats:sup>+<\/jats:sup> dendritic cells and three subsets of T cells (CD8<jats:sup>+<\/jats:sup>CD28<jats:sup>+<\/jats:sup>, CD3<jats:sup>+<\/jats:sup>TCRab<jats:sup>+<\/jats:sup>HLA-DR<jats:sup>+<\/jats:sup>, CD3<jats:sup>+<\/jats:sup>TCRgd<jats:sup>+<\/jats:sup>HLA-DR<jats:sup>+<\/jats:sup>) with a higher prognostic power than individual features (AUC = 0.825). Using this model, patients in the training cohort were divided into high- and low-risk groups with significant differences in mean progression-free survival (3.6 vs. 12.3 months), including disease control rate (41.2% vs. 91.7%), and objective response rate (17.6% vs. 41.6%). Integrating four-immune cell-subset based classifiers and three clinicopathologic risk factors can help to predict which patients might benefit from anti-PD-1 antibody inhibitors and remind potential non-responders to pursue effective treatment options in a timely way.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The prognostic immune risk score including the innate immune and adaptive immune cell populations could provide an accurate prediction efficacy in malignant melanoma patients with ICI therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1012673","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T05:48:51Z","timestamp":1670392131000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy\u2014a retrospective cohort study examining 66 circulating immune cell subsets"],"prefix":"10.3389","volume":"13","author":[{"given":"Peidong","family":"Chi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xizhi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiyue","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoshi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.32764","article-title":"Burden of melanoma in China, 1990-2017: Findings from the 2017 global burden of disease study","volume":"147","author":"Wu","year":"2020","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.12.006","article-title":"Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms","volume":"67","author":"Sun","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603801","article-title":"Melanoma incidence and mortality in Scotland 1979-2003","volume":"96","author":"MacKie","year":"2007","journal-title":"Br J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32984","article-title":"Outcomes after progression of disease with anti-Pd-1\/Pd-L1 therapy for patients with advanced melanoma","volume":"126","author":"Patrinely","year":"2020","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002949","article-title":"Ctla4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-Pd-1 based immunotherapy in clear cell renal cell carcinoma","volume":"9","author":"Klumper","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01051-z","article-title":"Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors","volume":"36","author":"Arora","year":"2019","journal-title":"Adv Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16016","article-title":"Association of combined pd-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma","volume":"34","author":"Bence","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.01055.x","article-title":"Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination","volume":"19","author":"Correll","year":"2010","journal-title":"Exp Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0761-z","article-title":"Circulating myeloid dendritic cells are increased in individuals with severe aplastic anemia","volume":"93","author":"Zonghong","year":"2011","journal-title":"Int J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0656","article-title":"Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: Cd1c+ dendritic cell frequency predicts progression-free survival","volume":"14","author":"van Cruijsen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.22240","article-title":"Statistical classification of multivariate flow cytometry data analyzed by manual gating: Stem, progenitor, and epithelial marker expression in nonsmall cell lung cancer and normal lung","volume":"83","author":"Normolle","year":"2013","journal-title":"Cytometry A"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-1900-1_23","article-title":"Multicolor flow cytometry and high-dimensional data analysis to probe complex questions in vaccinology","volume":"2414","author":"Cole","year":"2022","journal-title":"Methods Mol Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.192","article-title":"Statistical aspects of prognostic factor studies in oncology","volume":"69","author":"Simon","year":"1994","journal-title":"Br J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2833","article-title":"Variable selection for proportional odds model","volume":"26","author":"Lu","year":"2007","journal-title":"Stat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/bimj.200900064","article-title":"High-dimensional cox models: The choice of penalty as part of the model building process","volume":"52","author":"Benner","year":"2010","journal-title":"Biom J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models Via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J Stat Softw"},{"key":"B18","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687975","article-title":"Iobr: Multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures","volume":"12","author":"Zeng","year":"2021","journal-title":"Front Immunol"},{"key":"B24","article-title":"Modeling survival data: Extending the cox model (Statistics for biology and health)","author":"Therneau","year":"2000"},{"key":"B25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-Pd-1 monotherapy and anti-Pd-1\/Anti-Ctla-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"New Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12890-021-01636-x","article-title":"Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Pulm Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.575","article-title":"The frequency of T regulatory cells modulates the survival of multiple myeloma patients: Detailed characterisation of immune status in multiple myeloma","volume":"106","author":"Giannopoulos","year":"2012","journal-title":"Br J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2004.10.005","article-title":"Can Cd3+\/Hla-dr+ activated T cells predict the prognosis of non-hodgkin's lymphoma patients","volume":"97","author":"V\u00e1r\u00f3czy","year":"2005","journal-title":"Immunol Lett"},{"key":"B32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41598-019-57218-9","article-title":"Immune gene signatures for predicting durable clinical benefit of anti-Pd-1 immunotherapy in patients with non-small cell lung cancer","volume":"10","author":"Hwang","year":"2020","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158017","article-title":"Distinct immune signatures indicative of treatment response and immune-related adverse events in melanoma patients under immune checkpoint inhibitor therapy","volume":"22","author":"Reschke","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.131202998","article-title":"How the immune system works to protect the host from infection: A personal view","volume":"98","author":"Janeway","year":"2001","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190673","article-title":"Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis","volume":"217","author":"Lin","year":"2020","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0892-6","article-title":"Systemic dysfunction and plasticity of the immune macroenvironment in cancer models","volume":"26","author":"Allen","year":"2020","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-11-0097","article-title":"Characterization of human blood dendritic cell subsets","volume":"100","author":"MacDonald","year":"2002","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-038422","article-title":"Functional specialization of human circulating Cd16 and Cd1c myeloid dendritic-cell subsets","volume":"109","author":"Piccioli","year":"2007","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.11.6037","article-title":"Bdca-2, bdca-3, and bdca-4: Three markers for distinct subsets of dendritic cells in human peripheral blood","volume":"165","author":"Dzionek","year":"2000","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153818","article-title":"Cd14 expressing precursors give rise to highly functional conventional dendritic cells for use as dendritic cell vaccine","volume":"13","author":"Plantinga","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/cji.0000000000000297","article-title":"Blood immune cell biomarkers in patient with lung cancer undergoing treatment with checkpoint blockade","volume":"43","author":"M\u00f6ller","year":"2020","journal-title":"J immunotherapy (Hagerstown Md 1997)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted Cd8 T cells by pd-1-Targeted therapies is Cd28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Sci (New York NY)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2019.05.010","article-title":"Excessive expressions of T cell activation markers in pediatric immune thrombocytopenia","volume":"180","author":"Chen","year":"2019","journal-title":"Thromb Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.5603\/14717","article-title":"The role of tumor cells in the modification of T lymphocytes activity\u2013the expression of the early Cd69+, Cd71+ and the late Cd25+, Cd26+, Hla\/Dr+ activation markers on T Cd4+ and Cd8+ cells in squamous cell laryngeal carcinoma","volume":"49","author":"Starska","year":"2011","journal-title":"Part I. Folia histochemica cytobiologica"},{"key":"B46","doi-asserted-by":"publisher","first-page":"593","DOI":"10.5603\/FHC.2011.0082","article-title":"Prognostic value of the immunological phenomena and relationship with clinicopathological characteristics of the tumor\u2013the expression of the early Cd69+, Cd71+ and the late Cd25+, Cd26+, Hla\/Dr+ activation markers on T Cd4+ and Cd8+ lymphocytes in squamous cell laryngeal carcinoma","volume":"49","author":"Starska","year":"2011","journal-title":"Part Ii. Folia histochemica cytobiologica"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.2mr1219-233r","article-title":"\u0391\u03b2 and \u0393\u03b4 T cell receptors: Similar but different","volume":"107","author":"Morath","year":"2020","journal-title":"J leukocyte Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(02)00320-5","article-title":"Distinct structure and signaling potential of the gamma delta tcr complex","volume":"16","author":"Hayes","year":"2002","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588227","article-title":"Tissue resident memory \u0393\u03b4t cells in murine uterus expressed high levels of il-17 promoting the invasion of trophocytes","volume":"11","author":"Kang","year":"2020","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02389","article-title":"\u0393\u03b4 T lymphocytes: An effector cell in autoimmunity and infection","volume":"9","author":"Shiromizu","year":"2018","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1554175","article-title":"Boosting \u0393\u03b4 T cell-mediated antibody-dependent cellular cytotoxicity by pd-1 blockade in follicular lymphoma","volume":"8","author":"Rossi","year":"2019","journal-title":"Oncoimmunology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1550618","article-title":"Pd-1 signaling modulates interferon-\u0393 production by gamma delta (\u0393\u03b4) T-cells in response to leukemia","volume":"8","author":"Hoeres","year":"2019","journal-title":"Oncoimmunology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","article-title":"\u0393\u03b4 T cells: Pleiotropic immune effectors with therapeutic potential in cancer","volume":"19","author":"Silva-Santos","year":"2019","journal-title":"Nat Rev Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1012673\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T05:48:54Z","timestamp":1670392134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1012673\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2022.1012673"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1012673","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,7]]},"article-number":"1012673"}}